Stammdaten
Pharvaris N.V. ist ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung von Therapien für seltene Erkrankungen konzentriert, insbesondere bradykininvermittelte Angioödeme wie hereditäres Angioödem (HAE) und erworbenes Angioödem (AAE-C1INH). Das Hauptprodukt Deucrictibant ist ein oral verfügbarer, kleiner Molekül-Bradykinin-B2-Rezeptor-Antagonist. Es gibt zwei Formulierungen: eine sofort freisetzende Kapsel (IR) zur Behandlung akuter Angriffe und eine verlängert freisetzende Tablette (XR) zur Prophylaxe. Die IR-Kapseln zeigen in klinischen Studien schnelle Linderung der Symptome, mit einer medianen Zeit bis zum Beginn der Symptomlinderung von 1,28 Stunden und vollständiger Auflösung der Symptome innerhalb von 11,95 Stunden. Die XR-Tabletten reduzieren die monatliche Angriffshäufigkeit um 84,5% im Vergleich zu Placebo. Pharvaris führt derzeit Phase-3-Studien durch, darunter RAPIDe-3 für akute HAE-Behandlung und CHAPTER-3 für Prophylaxe. Das Unternehmen plant, eine Zulassungsantrag für Deucrictibant IR in der ersten Hälfte von 2026 einzureichen. Pharvaris hat ein starkes Team mit Erfahrung in der Entwicklung von Angioödem-Therapien und besitzt umfassende geistige Eigentumsrechte an Deucrictibant und verwandten Molekülen. Der globale Markt für HAE-Behandlungen wird auf etwa 2,7 Milliarden US-Dollar im Jahr 2024 geschätzt und soll bis 2036 auf 4,7 Milliarden US-Dollar wachsen. KI
Unternehmen & Branche
| Name | Pharvaris N.V. |
|---|---|
| Ticker | PHVS |
| CIK | 0001830487 |
| Börse | Nasdaq |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | N69605108 |
|---|---|
| ISIN | USN696051085 |
| Typ | Common Stock |
| Marktkapitalisierung | 2,40 Mrd. USD |
| Beta | -2,47 |
| Dividendenrendite | 0,00 % |
Sitz & Kontakt
| Sitz (Inkorporation) | Netherlands |
|---|---|
| Geschäftsadresse | J.H. OORTWEG 21 2333 CH LEIDEN, LEIDEN |
| Telefon | 31 (0)71 203 6410 |
| EIN (IRS) | 00-0000000 |
Listing & Historie
| Listing-Börsen | Nasdaq |
|---|---|
| Fiskaljahr-Ende | 31.12. |
| SEC-Filer-Status | Large accelerated filer |
| Frühere Namen | Pharvaris, B.V. (bis 2021) |
Externe Quelle:
SEC EDGAR »
Externe Links: Yahoo Finance » · OnVista »
Glück Conviction Score™ ⓘ
ⓘ
PHVS
Pharvaris N.V.
ⓘ
Eingeschränkte Aussagekraft — erst 59 % der Signal-Gewichte sind mit Daten unterlegt.
Effektiv
Schwach
Handelsvolumen
Mittel
Insider
0,0
Keine Insider-Käufe
Institutionell
31,5
7 neu, 34 erhöht, 34,6M $ netto
Aktivist
0,0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,71% (Stand: 30.06.2026)
Score-Verlauf (90 Tage)
Konviktions-Verlauf — oben stark · Mitte neutral · unten schwach
Farbzonen = Stärkestufen (Sehr schwach … Sehr stark). Exit-Score unter der Schwelle = Timing-Ausstieg. Komponenten per Legende einblenden.
Kursverlauf (24 Monate)
Indexierte Darstellung (Start = 100) — die Kursform bleibt sichtbar, absolute Kurse sind angemeldeten Mitgliedern vorbehalten.
Technische Indikatoren
Technical-Score basiert auf 12 Indikatoren (Trend, Momentum, Volatilität, Position) mit fixen Gewichten — wird aktuell nur informativ angezeigt und fließt nicht in den Glück Conviction Score ein. Integration nach Backtest-Kalibrierung (P5).
| Indikator | Signal | Gewicht | Wert | Detail | Beitrag |
|---|---|---|---|---|---|
| Kurs vs SMA50 | Bullisch | 10 % | 32.10 | +4.5 % vs SMA50 | |
| Kurs vs SMA200 | Bullisch | 15 % | 27.48 | +22.1 % vs SMA200 | |
| EMA20 vs EMA50 | Bullisch | 5 % | 34.00 | EMA50: 32.43 | |
| MACD-Histogramm | Bärisch | 10 % | -0.219 | Bearisch | |
| RSI(14) | Neutral | 10 % | 49.7 | Neutral (30–70) | |
| Stoch %K(14) | Bullisch | 5 % | 15.3 | Überverkauft | |
| ADX(14)+DI | Bullisch | 10 % | 34.7 | +DI: 19.9 / −DI: 13.4 | |
| Z-Score(60) | Neutral | 5 % | 0.87 | In Range | |
| 52W-Position | Bullisch | 5 % | 85.3 % | Hoch 35.96 / Tief 19.61 | |
| Bollinger(20,2σ) | Neutral | 5 % | 29.5 % | Upper 36.03 / Mid 34.27 / Lower 32.51 | |
| LinReg-Slope(60) | Bullisch | 10 % | +0.1120 | R²=0.77 / annualisiert +89.2 % |
Insider-Transaktionen (12 Monate) ⓘ
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-07-13 | Modig Berndt | Director, Officer, Chief Executive Officer | Open Market Sale | -2.292 | 34,97 | -80.154,45 | -33,2% | |
| 2026-06-30 | Schikan Johannes Gerardus Christiaan Petrus | Director | Open Market Sale | -30.712 | 35,49 | -1.090.048,73 | -451,5% | |
| 2026-06-30 | Lesage Anne | Officer, Chief Early Development | Open Market Sale | -30.703 | 35,49 | -1.089.637,19 | -451,3% | |
| 2026-06-30 | Lesage Anne | Officer, Chief Early Development | Open Market Sale | -27.872 | 35,48 | -988.890,20 | -409,6% | |
| 2026-06-29 | Schikan Johannes Gerardus Christiaan Petrus | Director | Open Market Sale | -2.400 | 35,10 | -84.249,84 | -34,9% | |
| 2026-06-29 | Lesage Anne | Officer, Chief Early Development | Open Market Sale | -2.300 | 35,12 | -80.785,66 | -33,5% | |
| 2026-06-29 | Lesage Anne | Officer, Chief Early Development | Open Market Sale | -8.300 | 35,05 | -290.907,53 | -120,5% | |
| 2026-06-29 | Lesage Anne | Officer, Chief Early Development | Open Market Sale | -6.997 | 35,05 | -245.231,56 | -101,6% | |
| 2026-06-29 | Schikan Johannes Gerardus Christiaan Petrus | Director | Open Market Sale | -6.888 | 35,05 | -241.447,13 | -100,0% | |
| 2026-06-26 | Lu Peng | Officer, Chief Medical Officer | Open Market Sale | -14.700 | 34,00 | -499.847,04 | -207,0% | |
| 2026-06-25 | Lu Peng | Officer, Chief Medical Officer | Open Market Sale | -11.600 | 34,45 | -399.674,52 | -165,5% | |
| 2026-06-25 | Lu Peng | Officer, Chief Medical Officer | Open Market Sale | -3.400 | 35,09 | -119.310,42 | -49,4% | |
| 2026-06-25 | Lesage Anne | Officer, Chief Early Development | Open Market Sale | -2.300 | 35,12 | -80.785,66 | -33,5% | |
| 2026-06-25 | Lesage Anne | Officer, Chief Early Development | Open Market Sale | -2.300 | 35,12 | -80.774,62 | -33,5% | |
| 2026-06-18 | Lu Peng | Officer, Chief Medical Officer | Open Market Sale | -300 | 34,00 | -10.200,00 | -4,2% | |
| 2026-06-15 | Modig Berndt | Director, Officer, Chief Executive Officer | Open Market Sale | -2.191 | 31,05 | -68.027,04 | -28,2% | |
| 2026-06-15 | Modig Berndt | Director, Officer, Chief Executive Officer | Open Market Sale | -100 | 31,46 | -3.146,00 | -1,3% | |
| 2026-06-04 | Nijdam Anna | Officer, Principal Accounting Officer | Open Market Sale | -2.670 | 30,87 | -82.425,04 | -34,1% | |
| 2026-05-22 | Nijdam Anna | Officer, Principal Accounting Officer | Open Market Sale | -5.501 | 30,74 | -169.084,24 | -70,0% | |
| 2026-05-21 | Nassif David W. | Officer, CFO / CLO | Open Market Sale | -10.000 | 30,31 | -303.076,00 | -125,5% | |
| 2026-05-21 | Monges Viviane | Director | Open Market Sale | -9.667 | 30,29 | -292.853,06 | -121,3% | |
| 2026-05-21 | Nijdam Anna | Officer, Principal Accounting Officer | Open Market Sale | -1.829 | 30,60 | -55.971,24 | -23,2% | |
| 2026-05-18 | Modig Berndt | Director, Officer, Chief Executive Officer | Open Market Sale | -2.292 | 29,22 | -66.976,82 | -27,7% | |
| 2026-05-15 | Abele Stefan Andreas | Officer, Chief Technical Ops Officer | Open Market Sale | -8.748 | 29,82 | -260.864,49 | -108,0% | |
| 2026-05-15 | Souverijns Wim | Officer, Chief Commercial Officer | Open Market Sale | -10.000 | 29,92 | -299.163,00 | -123,9% | |
| 2026-05-15 | Glassman Robert | Director | Open Market Sale | -4.667 | 29,82 | -139.154,54 | -57,6% | |
| 2026-05-15 | Glassman Robert | Director | Open Market Sale | -5.333 | 29,83 | -159.090,86 | -65,9% | |
| 2026-05-01 | Lu Peng | Officer, Chief Medical Officer | Open Market Sale | -143 | 31,00 | -4.433,00 | -1,8% | |
| 2026-05-01 | Lu Peng | Officer, Chief Medical Officer | Open Market Sale | -14.023 | 30,16 | -422.985,57 | -175,2% | |
| 2026-04-30 | Schikan Johannes Gerardus Christiaan Petrus | Director | Open Market Sale | -28.400 | 30,30 | -860.588,16 | -356,5% | |
| 2026-04-30 | Lu Peng | Officer, Chief Medical Officer | Open Market Sale | -15.000 | 30,24 | -453.627,00 | -187,9% | |
| 2026-04-30 | Lesage Anne | Officer, Chief Early Development | Open Market Sale | -3.700 | 30,26 | -111.946,46 | -46,4% | |
| 2026-04-30 | Lesage Anne | Officer, Chief Early Development | Open Market Sale | -19.200 | 30,26 | -580.909,44 | -240,6% | |
| 2026-04-30 | Lesage Anne | Officer, Chief Early Development | Open Market Sale | -18.000 | 30,26 | -544.604,40 | -225,6% | |
| 2026-04-30 | Schikan Johannes Gerardus Christiaan Petrus | Director | Open Market Sale | -670 | 31,03 | -20.791,51 | -8,6% | |
| 2026-04-29 | Lesage Anne | Officer, Chief Early Development | Open Market Sale | -3.700 | 30,08 | -111.280,46 | -46,1% | |
| 2026-04-29 | Lu Peng | Officer, Chief Medical Officer | Open Market Sale | -3.733 | 30,06 | -112.232,27 | -46,5% | |
| 2026-04-29 | Lesage Anne | Officer, Chief Early Development | Open Market Sale | -3.700 | 30,06 | -111.229,40 | -46,1% | |
| 2026-04-29 | Schikan Johannes Gerardus Christiaan Petrus | Director | Open Market Sale | -3.830 | 30,07 | -115.165,04 | -47,7% | |
| 2026-04-23 | Lu Peng | Officer, Chief Medical Officer | Open Market Sale | -100 | 30,03 | -3.003,00 | -1,2% | |
| 2026-04-23 | Schikan Johannes Gerardus Christiaan Petrus | Director | Open Market Sale | -100 | 30,03 | -3.003,00 | -1,2% | |
| 2026-04-23 | Lesage Anne | Officer, Chief Early Development | Open Market Sale | -100 | 30,03 | -3.003,00 | -1,2% | |
| 2026-04-23 | Lesage Anne | Officer, Chief Early Development | Open Market Sale | -100 | 30,03 | -3.003,00 | -1,2% | |
| 2026-04-22 | Lesage Anne | Officer, Chief Early Development | Open Market Sale | -7.000 | 30,05 | -210.357,70 | -87,1% | |
| 2026-04-22 | Schikan Johannes Gerardus Christiaan Petrus | Director | Open Market Sale | -7.000 | 30,05 | -210.378,70 | -87,1% | |
| 2026-04-22 | Lu Peng | Officer, Chief Medical Officer | Open Market Sale | -7.001 | 30,05 | -210.401,75 | -87,1% | |
| 2026-04-22 | Lesage Anne | Officer, Chief Early Development | Open Market Sale | -7.000 | 30,05 | -210.361,90 | -87,1% | |
| 2026-04-22 | Lesage Anne | Officer, Chief Early Development | Open Market Sale | -500 | 30,00 | -15.000,00 | -6,2% | |
| 2026-04-16 | Modig Berndt | Director, Officer, Chief Executive Officer | Open Market Sale | -2.292 | 28,60 | -65.558,53 | -27,2% | |
| 2026-04-09 | Modig Berndt | Director, Officer, Chief Executive Officer | Open Market Sale | -200 | 28,42 | -5.683,00 | -2,4% | |
| 2026-04-09 | Modig Berndt | Director, Officer, Chief Executive Officer | Open Market Sale | -23.133 | 27,74 | -641.598,38 | -265,7% |
Fondsaktivität (Vorquartalsvergleich) ⓘ
⚠ Vorläufige Daten: Erst 1693 von typischerweise 8373 Fonds (20 %) haben für das aktuelle 13F-Quartal eingereicht — Werte können sich in den kommenden Wochen noch deutlich ändern.
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| GENERAL ATLANTIC, L.P. | 8.031.252 | 0 | 8.031.252 | 226.882.869 | Neu | +100,0% | |
| FMR LLC | 6.284.472 | 0 | 6.284.472 | 177.536.335 | Neu | +100,0% | |
| Foresite Capital Management IV, LLC | 4.778.581 | 0 | 4.778.581 | 134.994.913 | Neu | +100,0% | |
| venBio Partners LLC | 4.639.304 | 0 | 4.639.304 | 131.060.338 | Neu | +100,0% | |
| VIKING GLOBAL INVESTORS LP | 3.653.310 | 0 | 3.653.310 | 103.206.008 | Neu | +100,0% | |
| EQT Fund Management S.a r.l. | 3.424.609 | 0 | 3.424.609 | 96.745.204 | Neu | +100,0% | |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 3.126.042 | 0 | 3.126.042 | 88.310.687 | Neu | +100,0% | |
| Bain Capital Life Sciences Investors, LLC | 2.675.509 | 0 | 2.675.509 | 75.583.129 | Neu | +100,0% | |
| WELLINGTON MANAGEMENT GROUP LLP | 2.118.900 | 0 | 2.118.900 | 59.858.926 | Neu | +100,0% | |
| Commodore Capital LP | 1.918.970 | 0 | 1.918.970 | 54.210.903 | Neu | +100,0% | |
| Novo Holdings A/S | 1.750.000 | 0 | 1.750.000 | 49.437.500 | Neu | +100,0% | |
| Saturn V Capital Management LP | 1.201.402 | 0 | 1.201.402 | 33.939.606 | Neu | +100,0% | |
| Point72 Asset Management, L.P. | 1.007.016 | 0 | 1.007.016 | 28.448.202 | Neu | +100,0% | |
| Cormorant Asset Management, LP | 1.000.000 | 0 | 1.000.000 | 28.250.000 | Neu | +100,0% | |
| Sofinnova Investments, Inc. | 818.328 | 0 | 818.328 | 23.117.766 | Neu | +100,0% | |
| 5AM Venture Management, LLC | 797.600 | 0 | 797.600 | 22.532.200 | Neu | +100,0% | |
| Polar Capital Holdings Plc | 781.016 | 0 | 781.016 | 22.063.702 | Neu | +100,0% | |
| BlackRock, Inc. | 757.213 | 0 | 757.213 | 21.391.267 | Neu | +100,0% | |
| Soleus Capital Management, L.P. | 702.052 | 0 | 702.052 | 19.832.969 | Neu | +100,0% | |
| Rock Springs Capital Management LP | 645.533 | 0 | 645.533 | 18.236.307 | Neu | +100,0% | |
| Kynam Capital Management, LP | 640.395 | 0 | 640.395 | 18.091.159 | Neu | +100,0% | |
| Patient Square Capital LP | 493.000 | 0 | 493.000 | 13.927.250 | Neu | +100,0% | |
| Ikarian Capital, LLC | 486.856 | 0 | 486.856 | 13.753.683 | Neu | +100,0% | |
| Elmind Capital, LP | 475.750 | 0 | 475.750 | 13.439.938 | Neu | +100,0% | |
| BALYASNY ASSET MANAGEMENT L.P. | 462.251 | 0 | 462.251 | 13.058.591 | Neu | +100,0% | |
| Eversept Partners, LP | 406.960 | 0 | 406.960 | 11.496.620 | Neu | +100,0% | |
| BAKER BROS. ADVISORS LP | 375.000 | 0 | 375.000 | 10.593.750 | Neu | +100,0% | |
| D. E. Shaw & Co., Inc. | 321.157 | 0 | 321.157 | 9.072.685 | Neu | +100,0% | |
| Tetragon Partners GP Ltd | 221.611 | 0 | 221.611 | 6.260.511 | Neu | +100,0% | |
| ORBIMED ADVISORS LLC | 205.400 | 0 | 205.400 | 5.802.550 | Neu | +100,0% | |
| Kalehua Capital Management LLC | 198.772 | 0 | 198.772 | 5.615.309 | Neu | +100,0% | |
| Foresite Capital Management V, LLC | 194.125 | 0 | 194.125 | 5.484.031 | Neu | +100,0% | |
| MILLENNIUM MANAGEMENT LLC | 181.946 | 0 | 181.946 | 5.139.974 | Neu | +100,0% | |
| Seven Fleet Capital Management LP | 172.731 | 0 | 172.731 | 4.879.651 | Neu | +100,0% | |
| CITADEL ADVISORS LLC | 168.630 | 0 | 168.630 | 4.763.798 | Neu | +100,0% | |
| Jones Hill Capital LP | 167.014 | 0 | 167.014 | 4.718.146 | Neu | +100,0% | |
| Octagon Capital Advisors LP | 165.000 | 0 | 165.000 | 4.661.250 | Neu | +100,0% | |
| MORGAN STANLEY | 164.323 | 0 | 164.323 | 4.642.125 | Neu | +100,0% | |
| BOOTHBAY FUND MANAGEMENT, LLC | 157.117 | 0 | 157.117 | 4.438.555 | Neu | +100,0% | |
| STATE STREET CORP | 152.945 | 0 | 152.945 | 4.320.696 | Neu | +100,0% | |
| SCHRODER INVESTMENT MANAGEMENT GROUP | 158.019 | 0 | 158.019 | 4.312.339 | Neu | +100,0% | |
| GOLDMAN SACHS GROUP INC | 142.929 | 0 | 142.929 | 4.037.745 | Neu | +100,0% | |
| TWO SIGMA INVESTMENTS, LP | 126.076 | 0 | 126.076 | 3.561.647 | Neu | +100,0% | |
| Alyeska Investment Group, L.P. | 125.000 | 0 | 125.000 | 3.531.250 | Neu | +100,0% | |
| ADAR1 Capital Management, LLC | 105.528 | 0 | 105.528 | 2.981.166 | Neu | +100,0% | |
| HighVista Strategies LLC | 97.866 | 0 | 97.866 | 2.764.715 | Neu | +100,0% | |
| Squarepoint Ops LLC | 96.384 | 0 | 96.384 | 2.722.848 | Neu | +100,0% | |
| GEODE CAPITAL MANAGEMENT, LLC | 89.129 | 0 | 89.129 | 2.517.541 | Neu | +100,0% | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 86.774 | 0 | 86.774 | 2.451.366 | Neu | +100,0% | |
| STEMPOINT CAPITAL LP | 86.637 | 0 | 86.637 | 2.447.495 | Neu | +100,0% |
Top-Fondshalter (Stand: 30.06.2026) ⓘ
⚠ Vorläufige Daten: Erst 1693 von typischerweise 8373 Fonds (20 %) haben für dieses Quartal eingereicht. Vollständigkeit erwartet bis 14.08.2026. Auswertungen (NEW/INC/DEC) sind noch zu konservativ — viele Spätfiler erscheinen aktuell als „Exits".
| Fonds | Anteile | Vorquartal (Stk) | Δ | Wert (USD) | Anteil (%) | Stimmkontrolle | Verlauf |
|---|---|---|---|---|---|---|---|
| Y-Intercept (Hong Kong) Ltd | 39.934 | 0 | +100,0% | 1.380.918 | 68,67 | 100 % | 3 Q |
| PSP Research LLC | 15.000 | 20.000 | -25,0% | 518.700 | 25,79 | 0 % | 3 Q |
| CoreCap Advisors, LLC | 2.700 | 0 | +100,0% | 93.366 | 4,64 | 0 % | 1 Q |
| 1620 INVESTMENT ADVISORS, INC. | 520 | 0 | +100,0% | 17.982 | 0,89 | 50 % | 1 Q |
Halter-Trend (6 Quartale)
| Periode | Status | Halter | Anteile (Mio) | Wert (Mio $) |
|---|---|---|---|---|
| 30.06.2026 | vorl. | 4 | 0,1 | 2 |
| 31.03.2026 | ✓ | 110 | 59,4 | 1.664 |
| 31.12.2025 | ✓ | 106 | 59,6 | 1.627 |
| 30.09.2025 | ✓ | 84 | 58,0 | 1.427 |
| 30.06.2025 | ✓ | 60 | 45,0 | 779 |
| 31.03.2025 | ✓ | 52 | 45,3 | 710 |
Top 10 Neueinsteiger
| Fonds | Anteile | Wert (USD) |
|---|---|---|
| Foresite Capital Management V, LLC | 194.125 | 5.484.031 |
| Jones Hill Capital LP | 167.014 | 4.718.146 |
| DIADEMA PARTNERS LP | 29.321 | 828.318 |
| Atom Investors LP | 9.100 | 257.075 |
| Persistent Asset Partners Ltd | 7.904 | 223.288 |
| SIMPLEX TRADING, LLC | 2.173 | 61.387 |
| Bare Financial Services, Inc | 6 | 170 |
Top 10 Aufstocker
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| Polar Capital Holdings Plc | 781.016 | 543.054 | +228.2 % | 22.063.702 |
| Point72 Asset Management, L.P. | 1.007.016 | 295.391 | +41.5 % | 28.448.202 |
| WELLINGTON MANAGEMENT GROUP LLP | 2.118.900 | 213.107 | +11.2 % | 59.858.926 |
| Seven Fleet Capital Management LP | 172.731 | 117.389 | +212.1 % | 4.879.651 |
| Sofinnova Investments, Inc. | 818.328 | 73.159 | +9.8 % | 23.117.766 |
| Saturn V Capital Management LP | 1.201.402 | 61.369 | +5.4 % | 33.939.606 |
| D. E. Shaw & Co., Inc. | 321.157 | 60.585 | +23.3 % | 9.072.685 |
| Qube Research & Technologies Ltd | 71.210 | 56.504 | +384.2 % | 2.011.683 |
| BlackRock, Inc. | 757.213 | 48.655 | +6.9 % | 21.391.267 |
| XTX Topco Ltd | 54.931 | 36.363 | +195.8 % | 1.551.801 |
Top 10 Verkäufer
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| Octagon Capital Advisors LP | 165.000 | -506.465 | -75.4 % | 4.661.250 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 442.256 | -499.349 | -53.0 % | 12.494 |
| Bain Capital Life Sciences Investors, LLC | 2.675.509 | -126.572 | -4.5 % | 75.583.129 |
| FMR LLC | 6.284.472 | -114.686 | -1.8 % | 177.536.335 |
| TWO SIGMA INVESTMENTS, LP | 126.076 | -89.112 | -41.4 % | 3.561.647 |
| MORGAN STANLEY | 164.323 | -84.011 | -33.8 % | 4.642.125 |
| Cormorant Asset Management, LP | 1.000.000 | -83.000 | -7.7 % | 28.250.000 |
| MILLENNIUM MANAGEMENT LLC | 181.946 | -66.912 | -26.9 % | 5.139.974 |
| UBS Group AG | 71.941 | -65.793 | -47.8 % | 2.032.333 |
| TD ASSET MANAGEMENT INC | 54.826 | -65.422 | -54.4 % | 1.548.835 |
Zusätzlich aktuell von 11 Mutual Funds/ETFs gehalten (N-PORT). Alle Fondsgesellschaften & ihre 4-Quartals-Bewegungen →
Aktivisten & Großaktionäre (13D/13G) ⓘ
| Datum | Investor | Typ | Anteil | Aktien | Δ | Δ-Balken |
|---|---|---|---|---|---|---|
| 15.05.2026 | Viking Global Opportunities Illiquid Investments Sub-Master LP (+6) | Passiv (13G/A) | 5,60 % | 3.653.310 | -1,40 pp | |
| 17.02.2026 | Bain Capital Life Sciences Opportunities III, LP | Passiv (13G/A) | 1,50 % | 993.314 | -0,30 pp | |
| 17.02.2026 | BCIP Life Sciences Associates, LP | Passiv (13G/A) | 0,30 % | 167.950 | 0,00 pp | |
| 17.02.2026 | Bain Capital Life Sciences Fund, L.P. | Passiv (13G/A) | 2,50 % | 1.640.817 | -0,50 pp | |
| 14.11.2025 | Bain Capital Life Sciences Opportunities III, LP | Passiv (13G/A) | 1,80 % | 1.122.481 | -0,50 pp | |
| 14.11.2025 | Bain Capital Life Sciences Fund, L.P. | Passiv (13G/A) | 3,00 % | 1.867.629 | -0,80 pp | |
| 14.11.2025 | BCIP Life Sciences Associates, LP | Passiv (13G/A) | 0,30 % | 191.165 | -0,10 pp | |
| 14.08.2025 | Venrock Healthcare Capital Partners III, L.P. (+6) | Passiv (13G/A) | 3,80 % | 2.047.620 | -2,70 pp | |
| 14.02.2024 | Venrock Healthcare Capital Partners III, L.P. (+6) | Passiv (13G/A) | 6,50 % | 3.395.606 | +0,40 pp | |
| 14.02.2024 | Viking Global Opportunities Illiquid Investments Sub-Master LP (+7) | Passiv (13G/A) | 7,00 % | 3.656.923 | -2,70 pp | |
| 13.02.2024 | Foresite Capital Management IV, LLC (“FCM IV”) (+2) | Passiv (13G/A) | 7,80 % | 4.038.842 | -2,40 pp | |
| 13.02.2024 | Foresite Capital Fund V, L.P. (“FCF V”) (+1) | Passiv (13G/A) | Ausstieg | 0 | Neu | |
| 13.02.2024 | General Atlantic Partners (Bermuda) EU, L.P. (+14) | Passiv (13G/A) | 14,10 % | 7.531.252 | +3,30 pp | |
| 08.02.2024 | LSP V Coöperatieve U.A. (+1) | Passiv (13G/A) | 6,80 % | 3.556.805 | Neu | |
| 25.01.2024 | Robert Adelman (+1) | Aktivist (13D/A) | 8,40 % | 4.382.504 | Neu | |
| 25.01.2024 | venBio Global Strategic Fund III, L.P. (+2) | Aktivist (13D/A) | 6,80 % | 3.547.504 | -3,60 pp | |
| 22.01.2024 | Bain Capital Life Sciences Opportunities III, LP | Passiv (13G/A) | 2,30 % | 1.182.217 | -1,80 pp | |
| 22.01.2024 | Bain Capital Life Sciences Fund, L.P. | Passiv (13G/A) | 3,80 % | 1.967.093 | -3,30 pp | |
| 22.01.2024 | BCIP Life Sciences Associates, LP | Passiv (13G/A) | 0,40 % | 201.347 | -0,30 pp | |
| 30.11.2023 | Venrock Healthcare Capital Partners III, L.P. (+6) | Passiv (13G) | 6,10 % | 2.483.606 | Neu | |
| 23.06.2023 | Bain Capital Life Sciences Fund, L.P. | Passiv (13G/A) | 7,10 % | 2.885.266 | -2,00 pp | |
| 23.06.2023 | Bain Capital Life Sciences Opportunities III, LP | Passiv (13G/A) | 4,10 % | 1.688.183 | Neu | |
| 23.06.2023 | BCIP Life Sciences Associates, LP | Passiv (13G/A) | 0,70 % | 295.335 | -0,20 pp | |
| 23.06.2023 | General Atlantic Partners (Bermuda) EU, L.P. (+14) | Passiv (13G/A) | 10,80 % | 4.406.252 | +3,50 pp | |
| 21.06.2023 | venBio Global Strategic Fund III, L.P. (+4) | Aktivist (13D/A) | 10,40 % | 4.264.672 | +3,50 pp | |
| 14.02.2023 | Viking Global Opportunities Illiquid Investments Sub-Master LP (+7) | Passiv (13G/A) | 9,70 % | 3.231.923 | +2,30 pp | |
| 13.02.2023 | Foresite Capital Management V, LLC (“FCM V”) (+1) | Passiv (13G/A) | 0,10 % | 34.142 | 0,00 pp | |
| 13.02.2023 | Foresite Capital Management IV, LLC (“FCM IV”) (+1) | Passiv (13G/A) | 9,60 % | 3.246.926 | -0,20 pp | |
| 13.02.2023 | James Tananbaum (“Tananbaum”) | Passiv (13G/A) | 9,70 % | 3.281.068 | -0,20 pp | |
| 26.09.2022 | venBio Global Strategic Fund III, L.P. (+4) | Aktivist (13D/A) | 6,90 % | 2.301.451 | -0,10 pp | |
| 14.02.2022 | Viking Global Opportunities Illiquid Investments Sub-Master LP (+7) | Passiv (13G/A) | 7,40 % | 2.455.536 | Neu | |
| 11.02.2022 | Foresite Capital Management IV, LLC (“FCM IV”) (+1) | Passiv (13G/A) | 9,80 % | 3.261.926 | Neu | |
| 11.02.2022 | James Tananbaum (“Tananbaum”) | Passiv (13G/A) | 9,90 % | 3.296.068 | Neu | |
| 11.02.2022 | Foresite Capital Management V, LLC (“FCM V”) (+1) | Passiv (13G/A) | 0,10 % | 34.142 | Neu | |
| 03.02.2022 | LSP V Coöperatieve U.A. (+1) | Passiv (13G) | 10,90 % | 3.607.566 | Neu |
Finanzkennzahlen (SEC XBRL · inkl. 20-F) ⓘ
Währung:
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 20-F | – | -206.446.791 $ | – | 354.209.624 $ | – |
| 2024-12-31 | 20-F | – | -139.442.744 $ | – | 302.709.243 $ | – |
| 2023-12-31 | 20-F | – | -111.466.950 $ | – | 440.557.384 $ | – |
| 2022-12-31 | 20-F | – | -81.416.305 $ | – | 178.904.000 $ | – |
| 2021-12-31 | 20-F | – | -48.396.880 $ | – | 240.213.208 $ | – |
| 2020-12-31 | 20-F | – | -31.887.057 $ | – | 124.059.341 $ | – |
| 2019-12-31 | 20-F | – | -9.017.714 $ | – | 23.139.431 $ | – |
| 2018-12-31 | 20-F | – | -4.939.432 $ | – | – | – |
Auslands-Jahresbericht (20-F, IFRS): value-Spalte USD-normalisiert (Engine-Wahrheit), Umschalter EUR/Original rechnet zum jeweiligen Periodenende um.
Einreichungs-Historie (10-K / 10-Q / 20-F / 6-K)
SEC-Einreichungs-Historie der letzten sechs Jahre (Datum = US-Kalendertag,
SEC/ET): Quartalsberichte (10-Q) und Jahresberichte (10-K); ausländische
Emittenten (ADR/Foreign Private Issuer) reichen stattdessen Jahresberichte
(20-F/40-F) und Zwischenmitteilungen (6-K) ein — dort liegt im SEC-Index
keine Berichtsperiode vor, Periode und Verzögerung bleiben leer. Die Spalte „Verzögerung" zeigt die
Tage zwischen Berichtsstichtag und tatsächlicher Einreichung.
Suffix /A kennzeichnet nachträgliche Berichtigungen.
| Eingereicht (US) | Form | Berichtsperiode | Verzögerung | |
|---|---|---|---|---|
| 26.06.2026 | 6-K | – | – | SEC » |
| 11.06.2026 | 6-K | – | – | SEC » |
| 12.05.2026 | 6-K | – | – | SEC » |
| 11.05.2026 | 6-K | – | – | SEC » |
| 02.04.2026 | 20-F | – | – | SEC » |
| 02.04.2026 | 6-K | – | – | SEC » |
| 12.01.2026 | 6-K | – | – | SEC » |
| 03.12.2025 | 6-K | – | – | SEC » |
| 12.11.2025 | 6-K | – | – | SEC » |
| 08.09.2025 | 6-K | – | – | SEC » |
| 12.08.2025 | 6-K | – | – | SEC » |
| 24.07.2025 | 6-K | – | – | SEC » |
| 10.07.2025 | 6-K | – | – | SEC » |
| 27.06.2025 | 6-K | – | – | SEC » |
| 10.06.2025 | 6-K | – | – | SEC » |
| 13.05.2025 | 6-K | – | – | SEC » |
| 07.04.2025 | 20-F | – | – | SEC » |
| 07.04.2025 | 6-K | – | – | SEC » |
| 13.01.2025 | 6-K | – | – | SEC » |
| 13.11.2024 | 6-K | – | – | SEC » |
| 25.09.2024 | 6-K | – | – | SEC » |
| 23.09.2024 | 6-K | – | – | SEC » |
| 05.09.2024 | 6-K | – | – | SEC » |
| 14.08.2024 | 6-K | – | – | SEC » |
| 28.06.2024 | 6-K | – | – | SEC » |
| 11.06.2024 | 6-K | – | – | SEC » |
| 10.04.2024 | 20-F | – | – | SEC » |
| 05.04.2023 | 20-F | – | – | SEC » |
| 29.03.2022 | 20-F | – | – | SEC » |
| 29.04.2021 | 20-F | – | – | SEC » |
Kapitalerhöhungen & Emissions-Historie
Emissions-Historie aus den finalen SEC-Prospekten: Börsengang (424B4) und Kapitalerhöhungen (424B5, Folge-/Sekundärplatzierungen). Volumen = Brutto-Erlös (bei Börsengängen zusätzlich der Ausgabepreis). Wiederholte Kapitalerhöhungen deuten auf Verwässerung der Altaktionäre hin.
| Datum (US) | Art | Volumen | |
|---|---|---|---|
| 08.05.2026 | Kapitalerhöhung | $115,0 Mio · $29,68/Aktie | SEC » |
| 24.07.2025 | Kapitalerhöhung | $175,0 Mio · $20,00/Aktie | SEC » |
| 22.07.2025 | Kapitalerhöhung | $150,0 Mio | SEC » |
| 07.12.2023 | Kapitalerhöhung | $282,0 Mio | SEC » |
| 24.08.2023 | Kapitalerhöhung | – | SEC » |
| 15.03.2022 | Kapitalerhöhung | $75,0 Mio | SEC » |
| 08.02.2021 | Börsengang | $165,4 Mio · $20,00/Aktie | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). Beträge in US-Dollar.
Fail-to-Deliver (6 Monate) ⓘ
| Datum | FTD-Menge | Kurs | Wert (USD) |
|---|---|---|---|
| 2026-06-30 | 38.038 | 34,71 | 1.320.299 |
| 2026-06-17 | 462 | 31,46 | 14.535 |
| 2026-06-15 | 4 | 30,72 | 123 |
| 2026-06-11 | 181 | 31,51 | 5.703 |
| 2026-06-10 | 203 | 31,60 | 6.415 |
| 2026-06-05 | 172 | 31,63 | 5.440 |